Mendel Haag, PhD, PharmD

CSL Seqirus, Netherlands

Disclosure(s): CSL Seqirus: Employment, Stocks/Bonds (Public Company)

Poster(s):

• (P-626) Relative Vaccine Effectiveness of Cell-Based Versus Egg-Based Quadrivalent Influenza Vaccines Against Test-Confirmed Influenza in the United States 2022-23 Influenza Season
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-707) Relative Effectiveness of Cell-Based Influenza Vaccines versus Egg-Based Influenza Vaccines: A Review of Test-Confirmed and Clinical Diagnosis-Based Outcomes
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-2364) Estimated Additional Burden Averted for the 2022-2023 influenza season from Use of Cell-Based Influenza Vaccines Compared to Egg-Based Influenza Vaccines Among People 0-64 Years of Age in the United States
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT